Pulvinar Neuro
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company does
Pulvinar Neuro is a neurotechnology company founded in 2016 in Durham, North Carolina by Dr. Flavio Frohlich as a spin-off from UNC. It develops non-invasive brain-stimulation research devices based on transcranial direct current stimulation (tDCS) and transcranial alternating current stimulation (tACS). Its flagship product, XCSITE 100, enables rigorous double-blind research with custom and high-powered stimulation, used in brain-stimulation labs across the US. It also won a $3.06 million NIH Phase II SBIR grant in 2023 for a cloud-enabled closed-loop stimulation device to treat depression.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Founded
Dr. Flavio Frohlich founded Pulvinar Neuro in Durham, NC as a UNC spin-off; launched XCSITE 100, its tDCS/tACS research solution.
- Acquired by EPI
In March 2022 Electromedical Products International (EPI), a Tillery Capital portfolio company and maker of the FDA-cleared Alpha-Stim, acquired Pulvinar Neuro to accelerate development and commercialization of its brain-stimulation technologies.
- $3M NIH grant
As an EPI subsidiary, Pulvinar Neuro was awarded a three-year, $3.06 million NIH Phase II SBIR grant (NIMH) to develop a cloud-enabled TCS device with a double-blind study in 30 patients with major depressive disorder.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.